Trial Profile
A Phase III Randomized, Double-Blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms NExUS
- Sponsors Bayer; Bayer HealthCare
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 15 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 08 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.